Key result
Type 1 diabetes linked to ~15% higher A-KIC to hepatic leucine enrichment ratio, unaffected by insulin.
Answers are grounded in this paper and cite their sources.
In human protein turnover studies with isotopically labeled leucine (Leu) as a tracer, plasma ketoisocaproate (KIC) enrichment is extensively used as a surrogate measure of intracellular leucine enrichment. To test how accurately arterial ketoisocaproate (A-KIC) represents leucine isotopic enrichment in the hepatic (HV) and femoral veins (FV), which drain liver and muscle beds, we measured Leu and KIC enrichments in samples collected from HV, FV, and femoral artery (A) in 24 control and 6 type I diabetic subjects after a primed, continuous infusion of L-[1-(13)C,(15)N]-Leu. Studies were performed during insulin deprivation or insulin replacement in the diabetic group, whereas the effect of normal saline or three different doses of insulin infusion (0.25, 0.50, and 1 mU. kg(-1). min(-1)) were assessed in healthy controls. The ratios of baseline isotopic enrichments of A-KIC to HV Leu and FV Leu were 0.93 +/- 0.01 and 0.94 +/- 0.02, respectively, in normal subjects and 1.07 +/- 0.04 and 1.05 +/- 0.03, respectively, in diabetic subjects (P < 0.01, diabetic vs. normal subjects). Insulin did not change A-KIC-to-HV Leu ratios in either group, but the A-KIC-to-FV Leu ratio decreased during insulin infusion in normal subjects (P < 0.05). In conclusion, A-KIC represents a reliable surrogate measure of HV Leu enrichment at different levels of circulating insulin in humans. The present data support the use of A-KIC as a surrogate precursor pool for hepatic protein synthesis.
No takes yet. Share an insight, caveat, or question.
Barazzoni et al. (1999) studied Type 1 diabetes mellitus and healthy controls (n=30). Primed, continuous L-[1-(13)C,(15)N]-leucine infusion with insulin modulation vs. Normal saline (in controls) or insulin deprivation (in diabetic subjects) was evaluated on Ratio of baseline isotopic enrichment of arterial ketoisocaproate (A-KIC) to hepatic vein (HV) leucine (p=< 0.01). Arterial ketoisocaproate to hepatic vein leucine enrichment ratios were 0.93 in controls vs 1.07 in type 1 diabetics (P<0.01) and remained unchanged by insulin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: